Chronos Wealth Management LLC Reduces Stake in Eli Lilly and Company $LLY

Chronos Wealth Management LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 2.6% in the first quarter, according to its most recent disclosure with the SEC. The fund owned 20,927 shares of the company’s stock after selling 557 shares during the period. Eli Lilly and Company makes up 9.3% of Chronos Wealth Management LLC’s investment portfolio, making the stock its biggest holding. Chronos Wealth Management LLC’s holdings in Eli Lilly and Company were worth $19,248,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in the business. Cottage Street Advisors LLC boosted its stake in Eli Lilly and Company by 10.9% in the 1st quarter. Cottage Street Advisors LLC now owns 2,040 shares of the company’s stock valued at $1,877,000 after buying an additional 200 shares in the last quarter. Louisiana State Employees Retirement System acquired a new position in Eli Lilly and Company in the first quarter valued at approximately $37,159,000. Aegis Wealth Management Inc. increased its holdings in Eli Lilly and Company by 0.7% in the first quarter. Aegis Wealth Management Inc. now owns 3,539 shares of the company’s stock valued at $3,255,000 after purchasing an additional 23 shares during the last quarter. Hoge Financial Services LLC increased its stake in Eli Lilly and Company by 2.1% in the first quarter. Hoge Financial Services LLC now owns 526 shares of the company’s stock valued at $478,000 after purchasing an additional 11 shares in the last quarter. Finally, Dorsey Wright & Associates bought a new position in Eli Lilly and Company in the first quarter valued at approximately $468,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: The European Medicines Agency’s CHMP recommended approval of Jaypirca (pirtobrutinib) for adults with chronic lymphocytic leukemia across all lines of therapy, which could expand Lilly’s oncology revenue opportunity in the EU. Article Title
• Positive Sentiment: Investors are also focused on Lilly’s obesity franchise, with new details on the Medicare GLP-1 Bridge program that could broaden access to Foundayo (orforglipron) and Zepbound for eligible Medicare Part D patients starting July 1. Article Title
• Positive Sentiment: Management’s expanded access push and continued clinical progress in obesity/diabetes are reinforcing the view that Lilly remains a leader in the weight-loss drug race, supporting bullish sentiment. Article Title
• Neutral Sentiment: Some recent coverage highlights Lilly’s strong pipeline and market leadership, but also notes valuation concerns and a less attractive entry point after the stock’s big run. Article Title
• Neutral Sentiment: News about Lilly launching its cancer drug Tanstrive in India adds another growth angle, but it appears to be a smaller near-term stock driver than the obesity and EU approval updates. Article Title

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on LLY. Rothschild & Co Redburn boosted their target price on shares of Eli Lilly and Company from $880.00 to $900.00 in a report on Thursday, May 7th. Sanford C. Bernstein reaffirmed an “outperform” rating on shares of Eli Lilly and Company in a research report on Monday, June 8th. Barclays raised their price objective on shares of Eli Lilly and Company from $1,350.00 to $1,400.00 and gave the stock an “overweight” rating in a research report on Monday, May 4th. Royal Bank Of Canada reiterated an “outperform” rating on shares of Eli Lilly and Company in a research note on Thursday, May 21st. Finally, UBS Group reiterated a “buy” rating on shares of Eli Lilly and Company in a research report on Wednesday, March 18th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $1,235.07.

Eli Lilly and Company Stock Up 7.0%

Shares of NYSE:LLY opened at $1,206.51 on Friday. Eli Lilly and Company has a 52-week low of $623.78 and a 52-week high of $1,215.76. The company has a market capitalization of $1.14 trillion, a PE ratio of 42.86, a price-to-earnings-growth ratio of 1.23 and a beta of 0.53. The company has a debt-to-equity ratio of 1.26, a quick ratio of 1.10 and a current ratio of 1.50. The company has a fifty day moving average of $1,036.28 and a 200-day moving average of $1,020.95.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $6.97 by $1.58. The business had revenue of $19.80 billion during the quarter, compared to analyst estimates of $17.82 billion. Eli Lilly and Company had a net margin of 34.98% and a return on equity of 105.77%. The firm’s quarterly revenue was up 55.5% on a year-over-year basis. During the same quarter last year, the business earned $3.34 EPS. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. On average, equities analysts predict that Eli Lilly and Company will post 35.8 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, September 10th. Investors of record on Friday, August 14th will be given a $1.73 dividend. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a yield of 0.6%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 24.58%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.